Unlike most peptides on the FDA's review schedule, GHK-Cu (copper peptide) has a split regulatory path: non-injectable routes are being removed from Category 1, while injectable routes are being removed from Category 2 and both are heading to Pharmacy Compounding Advisory Committee (PCAC) review before February 2027
PMID: 7133084 Sheth, N.K., et al
People who used aggressive weight loss medications or crash diets may face more significant laxity than those who lost weight steadily over a longer period
Human, animal, or adjacent evidence
This happens because semaglutide works by slowing down the emptying of your stomach, which can make you feel full and sometimes queasy
Metabotropic glutamate receptor type 5-dependent long-term potentiation of excitatory synapses on fast-spiking GABAergic neurons in mouse visual cortex